BDB-001 injection
DrugIntravenously administered
NCT Number: NCT05197842
The aim of the trial is to study the efficacy and safety of treatment with BDB-001 Injection substitution of glucocorticoid in patients with ANCA-associated vasculitis.
Looking for future studies?
Notify Me18 year–75 year
All sexes
Interventional
Phase 1 / Phase 2
The Second hospital Of Anhui Medical University, Hefei, Anhui, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Intravenously administered
Intravenously administered
Orally administered
Other names: Prednisone
Time frame: 12 weeks
Time frame: 12 weeks
Time frame: 4 weeks、8 weeks、12 weeks
Time frame: 12 weeks
Time frame: 4 weeks、8 weeks、12 weeks
Time frame: 0-24weeks
Safety and tolerability indexes of BDB-001 injection for multiple administration of ANCA-associated vasculitis(AAV) patients
Time frame: 0-24weeks
Safety and tolerability indexes of BDB-001 injection for multiple administration of ANCA-associated vasculitis(AAV) patients
Time frame: 0-12 weeks
Pharmacokinetic characteristics of BDB-001 injection in AAV patients were characterized based on population pharmacokinetic (PopPK) analysis.
Time frame: 0-12 weeks
Pharmacokinetic characteristics of BDB-001 injection in AAV patients were characterized based on population pharmacokinetic (PopPK) analysis.
Time frame: 0-12 weeks
Pharmacokinetic characteristics of BDB-001 injection in AAV patients were characterized based on population pharmacokinetic (PopPK) analysis.
Time frame: 0-12 weeks
Pharmacokinetic characteristics of BDB-001 injection in AAV patients were characterized based on population pharmacokinetic (PopPK) analysis.
Time frame: 0-12 weeks
Staidson (Beijing) Biopharmaceuticals Co., Ltd
Industry
A Multicenter, Randomized, Open-lable, Parallel-controlled, Phase I/II Trial to Study Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With ANCA-associated Vasculitis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05716334
ANCA-associated Vasculitis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Calgary, Alberta, Canada
View Trial DetailsNCT02994927
ANCA-associated Vasculitis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Huntsville, Alabama, United States
View Trial DetailsNCT02222155
ANCA-associated Vasculitis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Huntsville, Alabama, United States
View Trial DetailsNCT02108860
ANCA-associated Vasculitis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Los Angeles, California, United States
View Trial Details